



17th November 2017

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Please find enclosed Press Release dated 17th November 2017.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

Kedar Upadhye
Global Chief Financial Officer

Encl: as above



Press Release

Cipla Receives Final Approval for Generic Pulmicort Respules®

India, Mumbai, November 17, 2017: Cipla Ltd, a global pharmaceutical company, today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration (USFDA) to market a generic version of Astrazeneca's Pulmicort Respules®.

Cipla's Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL, are AN-rated generic equivalents of Astrazeneca's Pulmicort Respules® and are indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. The product is available for shipping immediately.

Pulmicort Respules® and generic equivalents had U.S. sales of approximately \$825M for the 12-month period ending September 2017, as reported by IMS Health.

About Cipla Ltd.

About Cipla Ltd. Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 80 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

www.cipla.com

Media Contacts:

Corporate Communications

Pallavi Golar

E Mail: pallavi.golar@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Naveen.Bansal1@Cipla.com